scholarly journals Kinetics and seroprevalence of SARS-CoV-2 antibodies – a comparison of 3 different assays

2021 ◽  
Author(s):  
Elisabeth Kahre ◽  
Lukas Galow ◽  
Manja Unrath ◽  
Luise Haag ◽  
Judith Blankenburg ◽  
...  
Keyword(s):  
Significant Loss ◽  
Trial Registration ◽  
Specific Assay ◽  
Registration Number ◽  
Antibody Levels ◽  
Antibody Kinetics

AbstractPurposeComparing seroprevalence and antibody kinetics in three different commercially available assays for SARS-CoV-2.MethodsSerostatus of COVID-19 patients was analyzed 5 months and 10 months after their infection, using three different assays: Diasorin LIAISON®, Euroimmun®, Abbott Diagnostics® ARCHITECT.ResultsSeropositivity at baseline differed significantly depending on the assay (Diasorin 81%, Euroimmun 83%, Abbott 59%). At follow-up antibody levels detected in the Diasorin assay were stable, while there was a significant loss in seropositivity in the Euroimmun and Abbott assays.ConclusionThere are significant differences in SARS-CoV-2 antibody kinetics based on the specific assay used.Trial registration number, date of registrationDRKS00022549, 29.07.2020 “retrospectively registered”

scholarly journals Kinetics and seroprevalence of SARS-CoV-2 antibodies – a comparison of 3 different assays

2021 ◽  
Author(s):  
Elisabeth Kahre ◽  
Lukas Galow ◽  
Manja Unrath ◽  
Luise Haag ◽  
Judith Blankenburg ◽  
...  
Keyword(s):  
Significant Loss ◽  
Trial Registration ◽  
Specific Assay ◽  
Registration Number ◽  
Antibody Levels ◽  
Antibody Kinetics

Abstract Purpose: Comparing seroprevalence and antibody kinetics in three different commercially available assays for SARS-CoV-2. Methods: Serostatus of COVID-19 patients was analyzed 5 months and 10 months after their infection, using three different assays: Diasorin LIAISON®, Euroimmun®, Abbott Diagnostics® ARCHITECT. Results: Seropositivity at baseline differed significantly depending on the assay (Diasorin 81%, Euroimmun 83%, Abbott 59%). At follow-up antibody levels detected in the Diasorin assay were stable, while there was a significant loss in seropositivity in the Euroimmun and Abbott assays. Conclusion: There are significant differences in SARS-CoV-2 antibody kinetics based on the specific assay used.Trial registration number, date of registration DRKS00022549, 29.07.2020 “retrospectively registered”

scholarly journals Kinetics and seroprevalence of SARS-CoV-2 antibodies: a comparison of 3 different assays

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Elisabeth Kahre ◽  
Lukas Galow ◽  
Manja Unrath ◽  
Luise Haag ◽  
Judith Blankenburg ◽  
...  
Keyword(s):  
Significant Loss ◽  
Specific Assay ◽  
Antibody Levels ◽  
Antibody Kinetics

AbstractComparing seroprevalence and antibody kinetics in three different commercially available assays for SARS-CoV-2. Serostatus of COVID-19 patients was analyzed 5 months and 10 months after their infection, using three different assays: Diasorin LIAISON, Euroimmun, Abbott Diagnostics ARCHITECT. Seropositivity at baseline differed significantly depending on the assay (Diasorin 81%, Euroimmun 83%, Abbott 59%). At follow-up antibody levels detected in the Diasorin assay were stable, while there was a significant loss in seropositivity in the Euroimmun and Abbott assays. There are significant differences in SARS-CoV-2 antibody kinetics based on the specific assay used.

scholarly journals A randomized control trial of phototherapy and 20% albumin versus phototherapy and saline in Kilifi, Kenya

2019 ◽  
Vol 12 (1) ◽  
Author(s):  
Dorcas N. Magai ◽  
Michael Mwaniki ◽  
Amina Abubakar ◽  
Shebe Mohammed ◽  
Anne L. Gordon ◽  
...  
Keyword(s):  
Exchange Transfusion ◽  
Controlled Trial ◽  
Rate Of Change ◽  
Trial Registration ◽  
Total Serum ◽  
Neurological Outcomes ◽  
End Of Treatment ◽  
Registration Number ◽  
Development Outcomes

Abstract Objective The study evaluated the efficacy of phototherapy and 20% albumin infusion to reduce total serum bilirubin (TSB) in neonates with severe hyperbilirubinemia. The primary outcome was a reduction of TSB at the end of treatment. The secondary outcomes were the need for exchange transfusion, inpatient mortality, neurological outcomes at discharge, and development outcomes at 12-months follow-up. Results One hundred and eighteen neonates were randomly assigned to phototherapy and 20% albumin (n = 59) and phototherapy and saline (n = 69). The median age at admission was 5 (interquartile range (IQR) 3–6) days, and the median gestation was 36 (IQR 36–38) weeks. No significant differences were found in the change in TSB (Mann–Whitney U =609, p = 0.98) and rate of change in TSB per hour after treatment (Mann–Whitney U = 540, p = 0.39) between the two groups. There were no significant differences between the two groups in the proportion of participants who required exchange transfusion (χ2 (2) = 0.36, p = 0.546); repeat phototherapy (χ2 (2) = 2.37, p = 0.123); and those who died (χ2 (2) = 0.92, p = 0.337). Trial registration The trial was registered in the International Standardized Randomized Controlled Trial Number (ISRCTN); trial registration number ISRCTN89732754.

scholarly journals Radiographic evaluation of a cross-shaped incision technique for thick-gingiva and thin-gingiva patients treated with implant-supported fixed prosthesis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Wen Luo ◽  
Xinyu Wang ◽  
Yaqian Chen ◽  
Yuping Hong ◽  
Yili Qu ◽  
...  
Keyword(s):  
Gingival Recession ◽  
Trial Registration ◽  
Radiographic Evaluation ◽  
Significant Difference ◽  
Registration Number ◽  
Bone Level ◽  
Fixed Prosthesis ◽  
Marginal Bone Level ◽  
Incision Technique

Abstract Background To evaluate a cross-shaped incision technique for thick-gingiva and thin-gingiva patients treated with implant-supported fixed prosthesis. Methods Total 55 patients receiving cross-shaped incision were assigned into thick-gingiva group (29 cases) and thin-gingiva group (26 cases). Follow-up was performed at 3 and 12-month after final restoration. Results Mesial and distal papilla height was significantly greater in thick-gingiva group than thin-gingiva group at 3 and 12 months, while periodontal depth and crestal marginal bone level around implant had no significant difference between the two groups during follow-up. No case of recession of buccal marginal gingiva was observed in thick-gingiva group. However, the recession of marginal gingiva of buccal aspect of the crown was found in 5 patients (19.2%) with thin-gingiva. Conclusions The cross-shaped incision may be applied to reconstruct gingival papillae and avoid the gingival recession in patients with thick-gingiva phenotype. Trial registration This study was registered at ClinicalTrials.gov (registration number NCT04706078, date 12 January 2021, Retrospectively registered).

scholarly journals The concept of a cementless isoelastic monoblock cup made of highly cross-linked polyethylene infused with vitamin E: Radiological analyses of migration and wear using EBRA and clinical outcomes at mid-term follow-up

2020 ◽  
Author(s):  
Yama Afghanyar ◽  
Sebastian Joser ◽  
Jonas Tecle ◽  
Philipp Drees ◽  
Jens Dargel ◽  
...  
Keyword(s):  
Vitamin E ◽  
Weight Bearing ◽  
Trial Registration ◽  
Harris Hip Score ◽  
Full Weight Bearing ◽  
Acetabular Bone ◽  
Total Wear ◽  
Radiological Data ◽  
Registration Number

Abstract BackgroundThe newest generation of cementless titanium coated, isoelastic monoblock cup with vitamin E-blended highly cross-linked polyethylene (HXLPE) has been introduced to the market in 2009. Aim of the present study was to obtain mid-term data including the analyses of migration and wear.MethodsThe present prospective study investigated 101 primary total hip arthroplasty (THA) cases in 96 patients at a single institution. Patients were allowed full weight-bearing on the first day postoperatively. Harris hip score (HHS) as well as pain and satisfication on visual analogue scale (VAS) were assessed during a mean follow-up of 79.0 months. Migration and wear were assessed using Einzel-Bild-Roentgen-Analyse (EBRA) software. Additionally, radiological alterations in the acetabular bone and complications were documented.ResultsAt mid-term follow-up (mean 79.0 months (range: 51.8 – 101.7)), 81 cases with complete clinical and radiological data were analyzed. In 42 hips utilisable EBRA measurements were obtained. HHS was 91.1 (range 38.0 – 100.0), satisfaction on VAS was 9.6 (range 6.0 – 10.0), rest pain on VAS was 0.2 (range 0.0 – 4.0), and load pain on VAS was 0.6 (range 0.0 – 9.0). Mean migration was 0.86 mm (range: 0.0 – 2.56) at 24 months and 1.34 mm (range: 0.09 – 3.14) at 5 years. Mean annual migration rate was 0.22 (range: -0.24 – 1.34). Mean total wear was 0.4 mm (range: 0.03 – 1.0). The mean annual wear rate was 0.06 mm per year (range: 0.0 – 0.17). Radiographic analysis showed osteolysis in none of the cases and no revision surgeries had to be performed.ConclusionUsing vitamin-E blended HXLPE in cementless isoelastic monoblock cups, no signs of osteolysis were obvious and no cases of aseptic loosening occurred. There was no need of revision surgery at mid-term. Values for cup migration and wear stay well below the benchmarks which are considered predictive for potential future failure.Trial registrationThe trial registration number on ClinicalTrial.gov: NCT04322916 (retrospectively registered at 26.03.2020).

scholarly journals The longitudinal kinetics of antibodies in COVID-19 recovered patients over 14 months

2021 ◽  
Author(s):  
Tsuf Eyran ◽  
Anna Vaisman-Mentesh ◽  
Yeal Dror ◽  
Ligal Aizik ◽  
Aya Kigel ◽  
...  
Keyword(s):  
Decision Making ◽  
Decay Rate ◽  
Natural Infection ◽  
Serological Response ◽  
Specific Antibodies ◽  
Antibody Levels ◽  
Antibody Kinetics ◽  
Kinetics Of

Here, we describe the longitudinal kinetics of the serological response in COVID-19 recovered patients over the period of 14 months. The antibody kinetics in a cohort of 200 recovered patients with 89 follow up samples at 2-4 visits reveal that RBD-specific antibodies decay over the period of 14 month following the onset of symptoms. The decay rate is associated with the robustness of the response thus, recovered patients that exhibit elevated antibody levels at the first visit, experience faster decay. We further explored the longitudinal kinetics differences between recovered patients and naive BNT162b2 vaccinees. We found a significantly faster decay in naive vaccinees compared to recovered patients suggesting that the serological memory following natural infection is more robust compared to vaccination. Our data highlights the differences between serological memory induced by natural infection vs. vaccination, facilitating the decision making in Israel regarding the 3rd dose vaccination.

scholarly journals The concept of a cementless isoelastic monoblock cup made of highly cross-linked polyethylene infused with vitamin E: radiological analyses of migration and wear using EBRA and clinical outcomes at mid-term follow-up

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Yama Afghanyar ◽  
Sebastian Joser ◽  
Jonas Tecle ◽  
Philipp Drees ◽  
Jens Dargel ◽  
...  
Keyword(s):  
Vitamin E ◽  
Weight Bearing ◽  
Trial Registration ◽  
Harris Hip Score ◽  
Full Weight Bearing ◽  
Link Type ◽  
Radiological Data ◽  
Registration Number ◽  
The Mean

Abstract Background The newest generation of cementless titanium-coated, isoelastic monoblock cup with vitamin E-blended highly cross-linked polyethylene (HXLPE) was introduced to the market in 2009. The aim of the present study was to obtain mid-term follow-up data including migration and wear analyses. Methods This prospective study investigated 101 primary total hip arthroplasty (THA) cases in 96 patients treated at a single institution. Patients were allowed full weight-bearing on the first day postoperatively. Harris hip score (HHS) and pain and satisfication on a visual analogue scale (VAS) were assessed at a mean follow-up of 79.0 months. Migration and wear were assessed using Einzel-Bild-Roentgen-Analyse (EBRA) software. Radiological acetabular bone alterations and complications were documented. Results At mid-term follow-up (mean 79.0 months, range: 51.8–101.7), 81 cases with complete clinical and radiological data were analyzed. Utilisable EBRA measurements were obtained for 42 hips. The mean HHS was 91.1 (range 38.0–100.0), VAS satisfaction was 9.6 (range 6.0–10.0), VAS rest pain was 0.2 (range 0.0–4.0), and VAS load pain was 0.6 (range 0.0–9.0). Mean migration was 0.86 mm (range: 0.0–2.56) at 24 months and 1.34 mm (range: 0.09–3.14) at 5 years, and the mean annual migration rate was 0.22 (range: − 0.24–1.34). The mean total wear was 0.4 mm (range: 0.03–1.0), corresponding to a mean annual wear rate of 0.06 mm per year (range: 0.0–0.17). Radiographic analysis did not reveal any cases of osteolysis, and no revision surgeries had to be performed. Conclusions After using vitamin-E blended HXLPE in cementless isoelastic monoblock cups, there were no obvious signs of osteolysis or aseptic loosening occurred. No patients required revision surgery after mid-term follow-up. Cup migration and wear values were well below the benchmarks considered predictive for potential future failure. Trial registration The trial registration number on ClinicalTrials.gov: NCT04322916 (retrospectively registered at 26.03.2020).

scholarly journals Immunoglobulin G Subclass Responses to Recombinant Em18 in the Follow-Up of Patients with Alveolar Echinococcosis in Different Clinical Stages

2010 ◽  
Vol 17 (6) ◽  
pp. 944-948 ◽  
Author(s):  
Dennis Tappe ◽  
Yasuhito Sako ◽  
Sonoyo Itoh ◽  
Matthias Frosch ◽  
Beate Grüner ◽  
...  
Keyword(s):  
Immunoglobulin G ◽  
Alveolar Echinococcosis ◽  
Staging System ◽  
Curative Surgery ◽  
Clinical Stages ◽  
Low Levels ◽  
Antibody Levels ◽  
Antibody Kinetics ◽  
Igg4 Antibody

ABSTRACT In this study, we compared the sequential responses of immunoglobulin G (IgG) subclasses to the diagnostic antigen Em18 in sera from patients with alveolar echinococcosis. A total of 225 sera from 36 patients at different clinical stages according to the WHO-PNM staging system were tested. The antibody responses were measured for cohorts with resected and unresected parasitic lesions by enzyme-linked immunosorbent assays (ELISA). Total IgG and, to a lesser extent, IgG4 antibody levels against Em18 correlated with all PNM stages before treatment, whereas levels of IgG2 were low and IgG3 was undetectable. Antibody kinetics, however, depended on the treatment rather than on the PNM stage. For some patients, after curative surgery, IgG1 antibodies dropped below the cutoff earlier than other antibodies, followed by total IgG and IgG4 within 18 months. For some patients with recurrences after surgery, IgG1 and IgG4 reappeared, whereas patients with unresectable lesions but stable disease showed steady declines in the levels of all antibodies, and IgG1 became undetectable in some patients. Additional testing of IgE responses to Em18 showed constantly low levels at all stages and in all cohorts.

Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial

2009 ◽  
Vol 69 (3) ◽  
pp. 571-574 ◽  
Author(s):  
W H Bos ◽  
B A C Dijkmans ◽  
M Boers ◽  
R J van de Stadt ◽  
D van Schaardenburg
Keyword(s):  
Rheumatoid Arthritis ◽  
Rheumatoid Factor ◽  
Randomised Trial ◽  
Dexamethasone Treatment ◽  
End Point ◽  
Preclinical Phase ◽  
Registration Number ◽  
Citrullinated Proteins ◽  
Antibody Levels

BackgroundRheumatoid arthritis is characterised by antibodies to citrullinated proteins (ACPA) and rheumatoid factor (RF) in the preclinical phase.ObjectiveTo determine whether an intervention aimed at decreasing autoantibody levels in people at risk may be effective in preventing progression to arthritis.Methods83 patients with arthralgia positive for ACPA or IgM-RF were randomly allocated to intramuscular injections of 100 mg dexamethasone or placebo at baseline and 6 weeks. The primary end point was a 50% antibody reduction or normalisation at 6 months.ResultsThe primary end point was reached in one patient in each group. Patients treated with dexamethasone had reductions of antibody levels after 1 month (ACPA 222% and IgM-RF 214%), which persisted at 6 months for ACPA. During a median follow-up of 26 months, arthritis development in both groups was similar (20% vs 21%).ConclusionIn autoantibody-positive patients with arthralgia, dexamethasone treatment decreases ACPA and IgM-RF levels, but does not prevent arthritis development.Trial registration number: ISRCTN73232918.

scholarly journals T1 glottic laryngeal cancer: the role of routine follow-up visits in detecting local recurrence

2021 ◽  
Author(s):  
Pihla Pakkanen ◽  
Taru Ilmarinen ◽  
Elina Halme ◽  
Heikki Irjala ◽  
Petri Koivunen ◽  
...  
Keyword(s):  
Medical Records ◽  
Laryngeal Squamous Cell Carcinoma ◽  
Treatment Method ◽  
Primary Treatment ◽  
Trial Registration ◽  
University Hospitals ◽  
Registration Number ◽  
Preservation Rate

Abstract Purpose We assessed the treatment outcome and the benefits of routine follow-up visits in T1 glottic laryngeal squamous cell carcinoma (LSCC). Methods Medical records of patients diagnosed with stage T1 glottic LSCC (N = 303) in five Finnish university hospitals between 2003 and 2015 were reviewed. Moreover, data from the Finnish Cancer Registry and the Population Register Center were collected. Results Of all 38 recurrences, 26 (68%) were detected during a routine follow-up visit, and over half (21 of 38, 55%) presented without new symptoms. Primary treatment method (surgery vs. radiotherapy) was not connected with 5-year disease-specific survival (DSS) or laryngeal preservation rate. Conclusion The majority of recurrences were detected on a routine follow-up visit, and local recurrences often presented without new symptoms. Routine post-treatment follow-up of T1 glottic LSCC seems beneficial. Trial registration Trial registration number and date of registration HUS/356/2017 11.12.2017.

Sign in / Sign up

Export Citation Format

Share Document